William Blair Predicts Neurogene's Q1 Earnings (NASDAQ:NGNE)

Neurogene Inc. (NASDAQ:NGNE - Free Report) - William Blair issued their Q1 2026 EPS estimates for Neurogene in a research note issued to investors on Tuesday, March 25th. William Blair analyst S. Corwin forecasts that the company will post earnings per share of ($1.18) for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Neurogene's current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene's Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($1.14) EPS and Q4 2026 earnings at ($1.16) EPS.

Neurogene (NASDAQ:NGNE - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.05. The firm had revenue of $0.93 million for the quarter.

Separately, HC Wainwright cut their target price on Neurogene from $55.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 25th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Neurogene currently has a consensus rating of "Buy" and a consensus target price of $59.80.

Neurogene Stock Performance

Neurogene stock traded down $0.81 during mid-day trading on Wednesday, reaching $14.52. 98,611 shares of the company were exchanged, compared to its average volume of 210,041. The firm has a market cap of $215.69 million, a PE ratio of -3.40 and a beta of 1.01. Neurogene has a twelve month low of $13.47 and a twelve month high of $74.49. The firm's 50-day simple moving average is $16.88 and its two-hundred day simple moving average is $28.76.

Remove Ads

Hedge Funds Weigh In On Neurogene

Several institutional investors and hedge funds have recently bought and sold shares of NGNE. Charles Schwab Investment Management Inc. boosted its stake in shares of Neurogene by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 30,317 shares of the company's stock worth $1,272,000 after acquiring an additional 741 shares in the last quarter. FMR LLC lifted its stake in shares of Neurogene by 912.4% in the third quarter. FMR LLC now owns 731,801 shares of the company's stock valued at $30,706,000 after buying an additional 659,515 shares during the period. BNP Paribas Financial Markets increased its position in shares of Neurogene by 192.8% during the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company's stock valued at $91,000 after purchasing an additional 1,429 shares during the period. MetLife Investment Management LLC acquired a new stake in shares of Neurogene during the 3rd quarter valued at about $254,000. Finally, RTW Investments LP grew its stake in shares of Neurogene by 6.0% in the 3rd quarter. RTW Investments LP now owns 1,135,256 shares of the company's stock valued at $47,635,000 after purchasing an additional 64,691 shares during the period. Hedge funds and other institutional investors own 52.37% of the company's stock.

Insider Activity at Neurogene

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of the business's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total transaction of $76,246.94. Following the sale, the chief financial officer now directly owns 72,343 shares of the company's stock, valued at $1,225,490.42. The trade was a 5.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.92% of the stock is currently owned by insiders.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.